Today the National Institute for Health and Care Excellence (NICE) is recommending objective testing with spirometry and Fractional Exhaled Nitric Oxide (FeNO) for most people with suspected asthma in both a primary and secondary care setting.
GPs, practice nurses, healthcare professionals in secondary care and tertiary asthma services should offer a FeNO test to adults (aged 17 and over) if a diagnosis of asthma is being considered. A FeNO test should also be considered for children and young people (aged 5 to 16) if there is diagnostic uncertainty after initial assessment and they have either normal spirometry or obstructive spirometry with a negative bronchodilator reversibility (BDR) test.
NICE have been working on the scoping, research, consultation and development of this guidance since early 2013 and have produced an extensive and authoritative document with detailed patient pathway algorithms to support assessment, testing and diagnosis.
More information on the Asthma: diagnosis and monitoring guidance can be found at:
BOSCH Healthcare Solutions have launched in November the new Vivatmo pro FeNO measurement device in the UK and Ireland via their distribution partner Healthcare 21. To find out more information about the Vivatmo pro or to arrange a demonstration and to purchase the device and its accessories please follow the link: